Moneycontrol PRO
Open App
you are here: HomeNewsBusiness

Lupin gets UK MHRA nod for generic drug to manage COPD, asthma

Lupin Healthcare (UK) has received approval from the Medicines and Healthcare Products Regulatory Agency (MHRA) to market a generic version of Spiriva, the Mumbai-based drug firm said in a statement.

August 26, 2022 / 02:32 PM IST
Lupin

Lupin

 
 
live
  • bselive
  • nselive
Volume
Todays L/H
More

Drug maker Lupin on Friday said its UK-based unit has received approval to market a generic product indicated for the management of chronic obstructive pulmonary disease (COPD) and asthma.

Lupin Healthcare (UK) has received approval from the Medicines and Healthcare Products Regulatory Agency (MHRA) to market a generic version of Spiriva, the Mumbai-based drug firm said in a statement.

Lutio, the company's product, has the potential to offer significant cost savings when available to UK patients, it added.

Lupin President EMEA Thierry Volle noted that the product provides an effective and high-quality treatment option to patients in the UK.

Lutio is the second inhalation product by Lupin Healthcare for the UK market after Luforbec pressurised metered dose inhaler (pMDI), Lupin stated. Shares of the company were trading 1.65 per cent down at Rs 654 apiece on the BSE.
PTI
first published: Aug 26, 2022 02:35 pm
Sections
ISO 27001 - BSI Assurance Mark